ADVERTISEMENT

Divi's Labs Q3 Review: Custom Synthesis Drives Earnings; Generics Stable — Motilal Oswal Retains 'Neutral'

Divi's current valuation provides limited upside from current levels, adds the brokerage.

<div class="paragraphs"><p>Colourful pills. (Source: unsplash)</p></div>
Colourful pills. (Source: unsplash)
Divi's Labs has been fortifying its growth drivers in custom synthesis through its focus on subsegments, such as peptides and contrast media. It is also adding newer molecules in the generics space.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit